Email
TextLatest News on Clinical Trials
miRagen Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult T-Cell Leukemia/Lymphoma at Two Upcoming Conferences
BOULDER, Colo., Jan. 23, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced that it will present new efficacy...
PharmaCyte Biotech Successfully Completes All Release Tests on Clinical Trial Product
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that both batches of the company’s manufactured...
The New England Journal of Medicine Publishes Comprehensive Data from Phase 3 Clinical Trial (OPTIC) of TEPEZZA™ (teprotumumab-trbw) for Thyroid Eye Disease
-- Phase 3 trial achieved its primary endpoint and all secondary endpoints with marked improvement in key indicators of disease -- January 22, 2020 05:20 PM Eastern Standard Time DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced...
Fishbat Explains How an Email Drip Campaign Can Benefit Patient Recruitment Companies
NEW YORK, Jan. 22, 2020 /PRNewswire/ -- By definition, an email drip campaign is a type of marketing process that entails the automated dissemination of emails. In addition to the ability to personalize messages, a drip campaign can be set to run during a designated...
BioLineRx Completes Recruitment in Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer
TEL AVIV, Israel, Jan. 22, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today the completion of patient recruitment in the triple combination arm of its ongoing Phase 2a...
Sirona Biochem: 100% Safety in Final Tox Study for Increased Concentration of TFC-1067
VANCOUVER, Jan. 22, 2020 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") announces that the final toxicology test, a Human Repeated Insult Patch Test ("HRIPT"), has successfully been completed. Sirona is now in preparation for the...
Asia-Pacific has a Record Year for Clinical Trials, according to Novotech CRO
SYDNEY, Jan 22, 2020 - (ACN Newswire) - Novotech CRO, the largest biotech CRO in Asia Pacific, says the region has had a record year for clinical trials in terms of the numbers of studies, experienced world-class sites and investigators, and patient enrollment....
Press release Biocartis Group: Biocartis Enters into Master Collaboration Agreement with AstraZeneca and Initiates EGFR Liquid Biopsy Study
Biocartis Enters into Master Collaboration Agreement with AstraZeneca and Initiates EGFR Liquid Biopsy Study Mechelen, Belgium, 22 January 2020 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART),...
Axsome Therapeutics Completes Patient Randomization in the STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression
NEW YORK, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the completion of patient...
OncoSec Secures Phesi ClinSite™ License to Select Clinical Trial Investigator Sites
Phesi, a data-driven provider of premier integrated clinical development analytics products and services, today announced that OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS) has purchased a multi-year ClinSite™ license to enable more accurate and precise...
Impressive Results Continue from CytoDyn’s Clinical Trials Evaluating Two Patients with Leronlimab, One in mTNBC and One in MBC
First patient with metastatic triple-negative breast cancer (mTNBC) continues to show no detectable circulating tumor cells (CTC) or putative metastatic tumor cells after 15 weeks of treatment with leronlimab in combination with carboplatin Second patient with stage 4...
Results from Influenza Challenge Study Published in Lancet Infectious DiseasesEfficacy of Oral Tablet Vaccine Compares Favorably to Market-Leading Fluzone®
SOUTH SAN FRANCISCO, Calif., Jan. 22, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, announced today that the results from its H1 influenza...
Notable Launches The ANSWer Study: An Observational Clinical Trial for Patients with Blood Cancer and Enrolls First Patients
SAN FRANCISCO, CA, UNITED STATES - Jan 22, 2020 - Notable, which is redefining cancer treatment with a clinically validated platform that rapidly advances drug development, is currently enrolling patients in its new observational clinical trial. The trial will take...
Ocuphire Pharma Announces In-License of Phase 2 Oral Small Molecule Drug Candidate for Diabetic Retinopathy and Diabetic Macular Edema from Apexian Pharmaceuticals
APX3330, a First-in-Class Ref-1 Inhibitor for Diabetic Ocular Diseases Affecting the Retina, Added to Ocuphire Portfolio of Ophthalmic Drug Candidates Data from Two Recently Completed Nyxol® Phase 2b Studies Accepted for Presentation at ARVO 2020 Conference FARMINGTON...
PharmaCyte Biotech Successfully Completes All Release Tests on Clinical Trial Product
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that both batches of the company’s manufactured...
Hoth Completes Animal Safety Study of Proprietary BioLexa Platform for the Treatment of Atopic Dermatitis
NEW YORK, Jan. 21, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing new generation therapies for dermatological and immunological disorders such as atopic dermatitis, psoriasis, asthma and acne, announced...
Ra Medical Systems Receives FDA IDE Approval to Begin Pivotal Atherectomy Clinical Study
Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces approval from the U.S. Food and Drug Administration (FDA) that the Company has provided sufficient...
BeiGene Announces that the Phase 3 Clinical Trial of its Anti-PD-1 Antibody Tislelizumab in Patients with First-Line Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis
BEIJING, China, and CAMBRIDGE, Mass., Jan. 21, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the...
Abivax Receives Clearance from U.S. FDA to Initiate Clinical Trials with ABX464 to treat Moderate to Severe Ulcerative Colitis
Active U.S. Investigational New Drug (IND) status extends Phase 2b clinical study in moderate to severe Ulcerative Colitis (UC) clinical trial to U.S. patients ABX464 Phase 2b UC trial is already ongoing in 15 European countries and Canada Enrollment of first U.S....
Stealth BioTherapeutics Initiates First-in-Human Study of SBT-272
BOSTON, Jan. 21, 2020 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the...